Samhouri Laith, Meheissen Mohamed A M, Ibrahimi Ahmad K H, Al-Mousa Abdelatif, Zeineddin Momen, Elkerm Yasser, Hassanein Zeyad M A, Ismail Abdelsalam Attia, Elmansy Hazem, Al-Hanaqta Motasem M, Al-Azzam Omar A, Elsaid Amr Abdelaziz, Kittel Christopher, Micke Oliver, Stummer Walter, Elsayad Khaled, Eich Hans Theodor
Department of Radiation Oncology, University Hospital Münster, Münster 48149, Germany.
Alexandria Clinical Oncology Department, Alexandria University, Alexandria 21500, Egypt.
Cancers (Basel). 2021 Aug 26;13(17):4308. doi: 10.3390/cancers13174308.
Central neurocytoma (CN) is a rare tumor accounting for <0.5% of all intracranial tumors. Surgery ± radiotherapy is the mainstay treatment. This international multicentric study aims to evaluate the outcomes of CNs patients after multimodal therapies and identify predictive factors.
We retrospectively identified 33 patients with CN treated between 2005 and 2019. Treatment characteristics and outcomes were assessed.
All patients with CN underwent surgical resection. Radiotherapy was delivered in 19 patients. The median radiation dose was 54 Gy (range, 50-60 Gy). The median follow-up time was 56 months. The 5-year OS and 5-year PFS were 90% and 76%, respectively. Patients who received radiotherapy had a significantly longer PFS than patients without RT ( = 0.004) and a trend towards longer OS. In addition, complete response after treatments was associated with longer PFS ( = 0.07).
Using RT seems to be associated with longer survival rates with an acceptable toxicity profile.
中枢神经细胞瘤(CN)是一种罕见肿瘤,占所有颅内肿瘤的比例不到0.5%。手术±放疗是主要治疗方法。这项国际多中心研究旨在评估多模式治疗后CN患者的预后并确定预测因素。
我们回顾性纳入了2005年至2019年间接受治疗的33例CN患者。评估了治疗特征和预后。
所有CN患者均接受了手术切除。19例患者接受了放疗。中位放疗剂量为54 Gy(范围50 - 60 Gy)。中位随访时间为56个月。5年总生存率(OS)和5年无进展生存率(PFS)分别为90%和76%。接受放疗的患者PFS显著长于未接受放疗的患者(P = 0.004),且OS有延长趋势。此外,治疗后完全缓解与更长的PFS相关(P = 0.07)。
使用放疗似乎与更长的生存率相关,且毒性可接受。